-- Martin Mackay, Ph.D., CEO, Chairman of the
Board and Co-Founder of Rallybio To Become Executive Chairman
--
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage
biotechnology company committed to identifying and accelerating the
development of life-transforming therapies for patients with severe
and rare diseases, today announced that Stephen Uden, M.D.,
Rallybio’s President, Chief Operating Officer and Co-Founder has
been appointed to the role of Chief Executive Officer, effective
August 1, 2023. Dr. Uden will remain President and will also be
appointed to Rallybio’s Board of Directors. The Company does not
expect to hire a replacement for Dr. Uden’s current role. He will
succeed Martin Mackay, Ph.D., Chief Executive Officer, Chairman of
the Board, and Co-Founder, who will assume the role of Executive
Chairman. As Executive Chairman, Dr. Mackay will remain a full-time
employee and continue to be actively involved with the Company,
with a particular focus on company strategy, investor relations and
related activities.
“It is a great privilege to lead Rallybio and our experienced
and talented team on our mission to establish the Company as a
leader in the development of transformative medicines for
underserved rare diseases. I am excited to build on our successes,
advance our clinical programs, and work tirelessly towards
delivering new product candidates from our discovery
collaborations. I look forward to continuing my close partnership
with Martin in his new role as Executive Chairman, as we, together
with our Board of Directors and our employees, continue to execute
Rallybio’s mission and strategy,” said Dr. Uden. “Looking ahead to
the rest of 2023, we expect results from our multiple dose cohort
Phase 1 study of RLYB212, our anti-HPA-1a monoclonal antibody
product candidate for the prevention of fetal and neonatal
alloimmune thrombocytopenia, in the fourth quarter of 2023. Our
multiple ascending dose Phase 1 study of RLYB116, an inhibitor of
complement component 5, also continues to progress, and we expect
to share initial data from this study, as well as details on our
initial indication strategy, in the fourth quarter of 2023.”
“Steve is a gifted leader with a deep commitment to Rallybio’s
values and stakeholders. Since the inception of Rallybio, Steve has
touched all aspects of Rallybio’s business and has been a leader in
setting the company’s direction and overseeing the day-to-day
operations,” said Dr. Mackay. “I am truly excited to continue our
partnership and share in the future success of Rallybio.”
Dr. Mackay continued, “The Board’s appointment of Steve as
Rallybio’s next CEO is the result of a carefully considered
succession plan which I am confident will best serve patients, our
employees and our shareholders, as we collectively advance our
broad portfolio of product candidates. Since the inception of
Rallybio, Steve has cemented its mission, and set our vision. Steve
has proven himself as a leader and played an integral role in the
development of the Company. The Board is confident in his ability
to lead the Company as we continue our work to establish Rallybio
as a premiere rare disease company.”
“On behalf of the Board of Directors, we are delighted to
appoint a leader of Steve’s caliber as the Company’s CEO,” said
Paula Soteropoulos, Director and Chair of the Compensation
Committee. “With Martin in his newly formed role as Executive
Chairman, and Steve as CEO, we look forward to seeing the Rallybio
team continue to execute on its priorities and build a sustainable,
world-class rare disease company.”
Dr. Uden co-founded Rallybio in 2018 and has served as the
Company’s President and Chief Operating Officer since 2018. He has
more than 25 years of experience, serving in R&D leadership
roles with global pharmaceutical and biotech companies. Dr. Uden
was previously Head of Research at Alexion Pharmaceuticals, Inc.,
where he led a series of collaborations and external alliances and
expanded Alexion’s research base beyond antibodies to include small
molecules, RNA-based therapies and broader protein engineering
capabilities. Prior to Alexion, Dr. Uden led research and
development groups in Japan for Wyeth and Novartis Oncology, and
held positions of increasing responsibility at Pfizer in the U.K.,
Japan and the U.S. Dr. Uden received his medical training at the
University of London’s St. Thomas’ Hospital Medical School, and
then practiced clinical and academic medicine within the U.K.’s
National Health Service and at the University of Manchester.
Dr. Mackay co-founded Rallybio and has served as Chief Executive
Officer and Chairman of the Board of Directors since 2018. Dr.
Mackay has over 30 years of R&D and leadership experience with
leading global pharmaceutical and biotechnology companies. He has
served as Executive Vice President and Global Head of Research
& Development at Alexion Pharmaceuticals, Inc., President of
Research & Development at AstraZeneca PLC, and President, Head
of Pharmatherapeutics Research and Development at Pfizer. Dr.
Mackay also has extensive experience serving on boards of public
companies. Since 2017, he has served on the board of directors of
Charles River Laboratories International, Inc., where he is
currently a member of the Science & Technology and Finance
committees. He also has served on the board of directors of Novo
Nordisk A/S since 2018, where he is currently Chair of the Research
& Development Committee and serves on the Remuneration
Committee. Dr. Mackay is a Senior Advisor at New Leaf Ventures and
previously served as a director of 5AM Acquisition Co. Dr. Mackay
earned a BSc First Class in microbiology from Heriot-Watt
University and a Ph.D. in molecular genetics from the University of
Edinburgh.
About Rallybio
Rallybio (NASDAQ: RLYB) is a clinical-stage biotechnology
company with a mission to develop and commercialize
life-transforming therapies for patients with severe and rare
diseases. Rallybio has built a broad pipeline of promising product
candidates aimed at addressing diseases with unmet medical need in
areas of maternal fetal health, complement dysregulation,
hematology, and metabolic disorders. The Company has two clinical
stage programs: RLYB212, an anti-HPA-1a antibody for the prevention
of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and
RLYB116, an inhibitor of complement component 5 (C5), with the
potential to treat several diseases of complement dysregulation, as
well as additional programs in preclinical development.
Rallybio is headquartered in New Haven, Connecticut with an
additional facility at the University of Connecticut’s Technology
Incubation Program in Farmington, Connecticut. For more
information, please visit www.rallybio.com and follow us on
LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements that are
based on our management’s beliefs and assumptions and on currently
available information. All statements, other than statements of
historical facts contained in this press release are
forward-looking statements. In some cases, forward-looking
statements can be identified by terms such as “may,” “will,”
“should,” “expect,” “plan,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “potential” or “continue” or the negative of these terms
or other similar expressions, although not all forward-looking
statements contain these words. Forward-looking statements in this
press release include, but are not limited to, statements
concerning, our mission to establish Rallybio as a leader in the
development of transformative medicines for underserved rare
diseases, new product candidates from our discovery collaborations,
the timing of the availability of data from the Phase 1 studies for
RLYB212 and RLYB116, our expectations regarding reporting of data
from such studies, our expectations regarding the usefulness of
data from such studies, and our ability to advance our portfolio.
The forward-looking statements in this press release are only
predictions and are based largely on management’s current
expectations and projections about future events and financial
trends that management believes may affect Rallybio’s business,
financial condition and results of operations. These
forward-looking statements speak only as of the date of this press
release and are subject to a number of known and unknown risks,
uncertainties and assumptions, including, but not limited to, our
ability to successfully initiate and conduct our planned studies,
including the FNAIT natural history study, and the Phase 1 and 1b
studies for RLYB212 and the Phase 1 study for RLYB116, and complete
such studies and obtain results on our expected timelines, or at
all, whether our cash resources will be sufficient to fund our
operating expenses and capital expenditure requirements and whether
we will be successful raising additional capital, our ability to
identify new product candidates and successfully acquire such
product candidates from third parties, our ability to enter into
strategic partnerships or other arrangements, including the
development of RLYB114, competition from other biotechnology and
pharmaceutical companies, and those risks and uncertainties
described in Rallybio’s filings with the U.S. Securities and
Exchange Commission (SEC), including Rallybio’s Quarterly Report on
Form 10-Q for the period ended March 31, 2023, and subsequent
filings with the SEC. The events and circumstances reflected in our
forward-looking statements may not be achieved or occur and actual
future results, levels of activity, performance and events and
circumstances could differ materially from those projected in the
forward-looking statements. Except as required by applicable law,
we are not obligated to publicly update or revise any
forward-looking statements contained in this press release, whether
as a result of any new information, future events, changed
circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230628281824/en/
Ami Bavishi Head of Investor Relations and Corporate
Communications (475) 47-RALLY (Ext. 282) abavishi@rallybio.com
Rallybio (NASDAQ:RLYB)
過去 株価チャート
から 4 2024 まで 5 2024
Rallybio (NASDAQ:RLYB)
過去 株価チャート
から 5 2023 まで 5 2024